Acurate neo (first generation) Boston Scientific, according to a press release announcing the company’s Q1 2020 financial results, has received the CE mark for its Acurate neo2 aortic valve system. The press release reports that the transcatheter aortic valve implantation (TAVI) system builds on the clinical performance of the original Acurate neo [...]
Boston Scientific has announced that its annual meeting of stockholders will be held exclusively in a virtual meeting format on 7 May 8am Eastern Time. The virtual meeting, which will be conducted via live audio webcast, is in response to the public health impact of the COVID-19, in accordance with orders issued by the [...]
Boston Scientific has revealed that its assuming the Q2 2020 impact of COVID-19 will be more significant than that of Q1 2020. As a result, the company is “taking proactive steps to reduce costs and be in a strong position to support customers and patients when healthcare systems begin to recover, and elective procedures [...]
Source: BIBA MedTech Insights TAVI Tracker The TAVI market in Western Europe grew by 19.2% between Q3 2018 and Q3 2019. Over the last three years, Edwards Lifesciences (the market leader) lost market share while Medtronic and Boston Scientific both gained market share. Boston Scientific’s acquisition of Symetis in Q2 2017 helped [...]
Source: BIBA MedTech LAA Monitor (quarterly) Data from the CAP and CAP2 registries—which contain the longest and largest follow-up of patients—add to previous evidence that left atrial appendage closure (LAAC) with Watchman (Boston Scientific) is a safe and effective alternative to long-term anticoagulation in patients with atrial fibrillation. Furthermore, the results show [...]
Michael Jaff Boston Scientific recently announced that vascular medicine specialist Michael R Jaff (Newton-Wellesley Hospital, Newton, USA) will be joining the company as vice president, clinical affairs, innovation and technology, peripheral interventions. His role will involve, according to Boston Scientific, leading clinical and medical affairs strategies to support the development and commercialisation [...]
Michael Jaff Michael R Jaff is to be vice president, clinical affairs, innovation and technology, peripheral interventions of Boston Scientific by January 2020. In this role, a press release reports, Jaff will lead clinical and medical affairs strategies to support the development and commercialisation of the company’s peripheral vascular medical device portfolio, [...]
Varian has completed its asset purchase of the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumours. According to a press release, this acquisition expands the portfolio of Varian interventional oncology solutions. Back in July, Varian revealed it had signed an asset purchase agreement to [...]
The FDA has issued a Class I recall—which it describes as “the most serious type of recall”—for the delivery system of the Sapien 3 Ultra transcatheter aortic valve implantation (TAVI) system. The recall follows Edwards Lifesciences receiving reports of burst balloons during implantation procedures, and it comes just under a week after the FDA [...]
Vercise Gevia Boston Scientific has announced the FDA approval of its ImageReady MRI labelling for the Vercise Gevia deep brain stimulation (DBS) system to be used in a full-body magnetic resonance imaging (MRI) environment. This system, with the Vercise Cartesia directional lead, is designed to treat the symptoms of Parkinson’s disease by [...]
Varian has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumours. The planned acquisition of the drug-loadable microsphere (Oncozene/Embozene Tandem) and bland embolic (Embozene) bead products, a press release reports, will enable Varian to extend its new [...]